Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
The Japanese Society for Regenerative Medicine
Kobe, Japan
A
5001-10000 Employees
2001
Key takeaway
The Japanese Society for Regenerative Medicine has commented on the approval process for regenerative medicine products in Japan and has launched the "REAP" service, a data registration system aimed at facilitating unrestricted clinical practice in this field.
Reference
Core business
The Japanese Society for Regenerative Medicine
Orchestrating Wisdom to Innovate, Universalize for the Happiness and Future of All Human Beings.
ReproCELL
Yokohama, Japan
A
51-100 Employees
2003
Key takeaway
REPROCELL is actively developing novel regenerative medicine therapies, particularly for neurodegenerative diseases, utilizing its expertise in pluripotent stem cells and mesenchymal stem cells.
Reference
Core business
REPROCELL Global
Want to better translate your discoveries into therapies? Speak to our human tissue and stem cell experts about your research challenges.
Minaris Regenerative Medicine
Tokyo, Japan
A
501-1000 Employees
-
Key takeaway
Minaris Regenerative Medicine is a prominent contract development and manufacturing organization specializing in the production of cell and gene therapy products. With over 20 years of experience, they provide comprehensive manufacturing services and have advanced facilities across the globe, positioning them as a key player in the regenerative medicine sector.
Reference
Service
QP Batch Certification | Minaris Regenerative Medicine
For cell and gene therapy products manufactured outside the European Union, Minaris Regenerative Medicine offers batch release to the EU market by Qualified Persons (QP).
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Restore Vision
Tokyo, Japan
A
1-10 Employees
2016
Key takeaway
Restore Vision is a startup in Japan focused on developing gene therapy for visual restoration, which aligns with the principles of regenerative medicine.
Reference
Core business
株式会社レストアビジョン
Restore Vision is a startup based in Japan aiming to develop a visual restoration gene therapy.
NEXTGEM INC.
Tokyo, Japan
A
11-50 Employees
2016
Key takeaway
NextGeM Inc. focuses on next-generation regenerative medicine innovations using tissue stem cells, aiming to provide ultimate curative treatments with fewer side effects. Their vision includes the integration of cutting-edge bio-digital technologies to drive medical advancements and create a platform for researchers to thrive.
Reference
Core business
ネクスジェン株式会社 - 組織幹細胞を用いた次世代再生医療イノベーション - NextGeM Inc.
ネクスジェン株式会社は、組織幹細胞を用いた次世代再生医療イノベーションにより、副作用の少ない究極の根治治療の提供を目指します。最先端のバイオ・デジタル技術の融合による次世代医療イノベーションの実現と、多くの研究者が活躍できるプラットフォームの創造を目指します。
VC Cell Therapy
Kyōtango, Japan
A
- Employees
2021
Key takeaway
The company is focused on developing high-quality cells for clinical use, which is essential in regenerative medicine, particularly for treating retinal degenerative diseases like age-related macular degeneration. They are also exploring logistics to provide innovative therapies, including autologous cell therapy, where patients' own cells are used for treatment.
Reference
Core business
株式会社VC Cell Therapy
NEWS
Stem Cell & Device Laboratory
Kyoto, Japan
A
1-10 Employees
2014
Key takeaway
The company specializes in biomaterials research, particularly focusing on a functional neuron maturation device that enhances the application of microelectrode arrays for measuring neural networks. This innovation is relevant to regenerative medicine as it supports the development and integration of functional neural tissues.
Reference
Product
PRODUCTS・SERVICES | Stem Cell & Device Laboratory, Inc.
T Cell Nouveau
Tokyo, Japan
A
1-10 Employees
2021
Key takeaway
The company, T Cell Nouveau Inc., is making significant strides in regenerative medicine through its innovative Hybrid CAR T-cell therapy, which aims to effectively treat solid tumors that are resistant to traditional CAR and TCR-T cell therapies. Their unique approach focuses on enhancing the immune response against specific cancer antigens, potentially revolutionizing cancer treatment.
Reference
Core business
Car-t細胞療法 | T Cell Nouveau、ティーセルヌーヴォー株式会社 | 東京都
ティーセルヌーヴォー株式会社は臨床段階のバイオメディカル企業であり、三重大学 珠玖研究室が開発した最先端のTCR like CAR-T細胞療法を用いて、免疫系を賦活化することにより固形がんを治療することを目指しています。私たちのユニークなTCR like CAR T細胞療法は、近年のCAR-T細胞療法あるいはTCR-T細胞療法が奏功しない固形がんの治療を目指す飛躍的な革新技術であると強く信じています。私たちの特許技術であるTCR like CAR抗体は、ペプチド-HMC複合体における標的抗原（MAGE4またはPRAME）に対して高い特異性を有しています。さらに、私たちの特許技術であるシグナルドメイン構造は、免疫抑制性のがん微小環境において、T cell機能の活性化、維持及び持続を助けます。
Libra Medicina
Sapporo, Japan
A
1-10 Employees
2009
Key takeaway
LibraMedicina Ltd. is dedicated to creating new medicines and medical devices, aiming to improve health and the quality of life for patients with serious illnesses. Their intermediary services for contract R&D and GMP manufacturing of biopharmaceuticals highlight their commitment to advancing medical innovation.
Reference
Core business
Access - リブラメディシーナ
LibraMedicina Inc. Add :3-11-5, Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023 TEL：03-6712-7668 FAX：03-6712-7669 E-Mail ： biz@lmed.co.jp HP ： http://www.lmed.co.jp Nihonbashi Life Science Building2 ■Tokyo Metro Hibiya Line 3-minute walk from Kodenmacho Station ■JR Sobu Line 3-minute walk from Shin-Nihonbashi Station ■Tokyo Metro Ginza Line / Hanzomon Line 5-minute walk from Exit #A9 of Mitsukoshimae Station
Thyas Co. Ltd.
Kyoto, Japan
A
1-10 Employees
2015
Key takeaway
The company, サイアス株式会社, specializes in regenerating T cells from human iPS cells, focusing on developing regenerative immune cell therapies for cancer and infectious diseases. Their work is supported by expertise in iPSC differentiation and relevant regulatory knowledge, making significant contributions to the field of regenerative medicine.
Reference
Core business
サイアス株式会社
サイアス株式会社はヒトiPS細胞からT細胞を再生し、がんや感染症に対する再生免疫細胞療法の製剤を提供することを事業目的としています。
Technologies which have been searched by others and may be interesting for you:
When exploring the Regenerative Medicine industry in Japan, several key considerations are essential. The country has a robust regulatory framework that governs the development and commercialization of regenerative therapies. The Pharmaceuticals and Medical Devices Agency (PMDA) oversees these regulations, ensuring safety and efficacy while promoting innovation. It is crucial to be aware of Japan's unique legal framework, including the Act on the Safety of Regenerative Medicine, which streamlines the approval process for cell and tissue-based therapies. Challenges in the industry include high research and development costs and the need for specialized expertise in advanced technologies such as stem cell research and gene editing. However, Japan also presents significant opportunities, given its strong emphasis on biotechnology and aging population, which drives demand for regenerative therapies. Additionally, collaboration with academic institutions and strong government support further enhance the industry's potential. Environmental concerns related to the production and disposal of biological materials are also important, as sustainability practices are increasingly prioritized. The competitive landscape features both established firms and startups, fostering innovation and diverse solutions. Japan's position in the global market is notable, as it is a leader in regenerative medicine research and development, attracting international partnerships and investments. Understanding these factors is crucial for anyone interested in entering or investing in this dynamic field.
Some interesting numbers and facts about your company results for Regenerative Medicine
| Country with most fitting companies | Japan |
| Amount of fitting manufacturers | 24 |
| Amount of suitable service providers | 20 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2001 |
| Youngest suiting company | 2021 |
Some interesting questions that has been asked about the results you have just received for Regenerative Medicine
What are related technologies to Regenerative Medicine?
Based on our calculations related technologies to Regenerative Medicine are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of Regenerative Medicine?
Start-Ups who are working in Regenerative Medicine are T Cell Nouveau
Which industries are mostly working on Regenerative Medicine?
The most represented industries which are working in Regenerative Medicine are Other, Biotechnology, Medical, IT, Software and Services, Pharmaceuticals
How does ensun find these Regenerative Medicine Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.